The proto-oncogene Pim-1 is a target of miR-33a

Oncogene

Volumn 31, Issue 7, 2012, Pages 918-928

  Thomas, M ^a   Lange Grunweller K ^a   Weirauch, U ^a   Gutsch, D ^a   Aigner, A ^a   Grunweller A ^a   Hartmann, R K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

microRNA; miR 33a; Pim 1; proliferation; RNAi; siRNA

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 6; MICRORNA; MICRORNA 33A; PROTEIN KINASE PIM 1; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CARCINOMA; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HEP G2 CELLS; HUMANS; K562 CELLS; MICRORNAS; MOLECULAR MIMICRY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSFECTION;

EID: 84857122981     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.278     Document Type: Article

References (58)

1. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. (2004). Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43-49. (Pubitemid 38992921)
2. Amaravadi R, Thompson CB. (2005). The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624. (Pubitemid 41434384)
3. Aqeilan RI, Calin GA, Croce CM. (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
4. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Mö röy T. (2004). The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319-48328. (Pubitemid 39540988)
5. Bachmann M, Mö rö y T. (2005). The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726-730. (Pubitemid 40202995)
6. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. Review.
7. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233. Review.
8. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
9. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. (2010). PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004-1015. Review.
10. Brennecke J, Stark A, Russell RB, Cohen SM. (2005). Principles of microRNA-target recognition. PLoS Biol 3: e85.
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-21559.
12. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004. (Pubitemid 38327724)
13. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. (2005a). Real-time quantification of microRNAs by stem-loop RTPCR. Nucleic Acids Res 33: e179.
14. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. (2005b). Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3: 443-451. (Pubitemid 41232606)
15. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949. (Pubitemid 41377683)
16. Croce CM. (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714. Review.
17. Crowell JA, Steele VE, Fay JR. (2007). Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148. (Pubitemid 47294742)
18. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 91: 231-241. (Pubitemid 27456390)
19. Esquela-Kerscher A, Slack FJ. (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269. Review.
20. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. (2003). The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17: 1841-1854. (Pubitemid 36944562)
21. Gangaraju VK, Lin H. (2009). MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 10: 116-125.
22. Garzon R, Calin GA, Croce CM. (2009). MicroRNAs in cancer. Annu Rev Med 60: 167-179.
23. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105. (Pubitemid 46991392)
24. Grü nweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 20-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31: 3185-3193. (Pubitemid 37441778)
25. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M et al. (2010). miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 15: 3277-3285.
26. Huang J, Manning BD. (2009). A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217-222.
27. Ibrahim AF, Weirauch U, Thomas M, Grü nweller A, Hartmann RK, Aigner A et al. (2011). MiRNA replacement therapy through PEImediated in vivo delivery of miR-145 or miR-33a in colon carcinoma. Cancer Res (doi:10.1158/0008-5472. CAN-10-4645).
28. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070. (Pubitemid 41161233)
29. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635-647. (Pubitemid 40343076)
30. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
31. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
32. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. (2005). MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7: 719-723. (Pubitemid 40975754)
33. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM et al. (2007). Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14: 2009-2023. (Pubitemid 47578159)
34. Meyerson M, Harlow E. (1994). Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086.
35. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J et al. (2004). Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24: 6104-6115. (Pubitemid 38787993)
36. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. (1999). Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659-18666.
37. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N et al. (2007). Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467-1475. (Pubitemid 350224243)
38. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE et al. (2010). MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328: 1566-1569.
39. Nawijn MC, Alendar A, Berns A. (2011). For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11: 23-34. Review.
40. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843. (Pubitemid 40839736)
41. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C et al. (2005). Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130-6137. (Pubitemid 40280098)
42. Rayner KJ, Suá rez Y, Dá valos A, Parathath S, Fitzgerald ML, Tamehiro N et al. (2010). miR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570-1573.
43. Rehwinkel J, Behm-Ansmant I, Gatfield D, Izaurralde E. (2005). A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing. RNA 11: 1640-1647. (Pubitemid 41505538)
44. Selbach M, Schwanhä usser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
45. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M et al. (2009). Regression of murine lung tumors by the let-7 microRNA. Oncogene 29: 1580-1587.
46. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T et al. (1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56: 673-682. (Pubitemid 19065532)
47. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU et al. (2007). Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+cells. Blood 109: 4399-4405. (Pubitemid 46743409)
48. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. (1991). Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 11: 1176-1179. (Pubitemid 21895472)
49. Wang HW, Noland C, Siridechadilok B, Taylor DW, Ma E, Felderer K et al. (2009). Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol 16: 1148-1153.
50. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. (2002). Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45-55. (Pubitemid 35335911)
51. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W et al. (2009). Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52: 74-86.
52. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H et al. (2006). The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25: 70-78. (Pubitemid 43050005)
53. Yang ZZ, Tschopp O, Baudry A, Dü mmler B, Hynx D, Hemmings BA. (2004). Physiological functions of protein kinase B/Akt. Biochem Soc Trans 32: 350-354. Review. (Pubitemid 38582126)
54. Zhang T, Zhang X, Ding K, Yang K, Zhang Z, Xu Y. (2010). PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo. J Surg Oncol 101: 513-519.
55. Zhang W, Shay JW, Deisseroth A. (1993). Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 15: 4772-4775. (Pubitemid 23326164)
56. Zhang Y, Wang Z, Li X, Magnuson NS. (2008). Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27: 4809-4481.
57. Zhang Y, Wang Z, Magnuson NS. (2007). Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5: 909-922. (Pubitemid 47416668)
58. Zippo A, De Robertis A, Serafini R, Oliviero S. (2007). PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 9: 932-944. (Pubitemid 47190448)